Cancer Pharmacologist and HTS Scientist

癌症药理学家和 HTS 科学家

• 批准号: 10320283
• 负责人: Joshua A. Bauer
• 金额: $ 21.9万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-09-19 至 2026-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10320283
• 关键词: 3-Dimensional; Applications Grants; Area; Award; Biochemistry; Biological Assay; Biology; CRISPR library; Cancer Biology; Cancer Center; Cancer Research Project; Chemicals; Clinical Trials Design; Clustered Regularly Interspaced Short Palindromic Repeats; Collaborations; Comprehensive Cancer Center; Computer software; Core Facility; Development; Drug Screening; Educational workshop; Exposure to; Funding; Genomic approach; Genomics; Goals; Image; Institutes; Investigational Drugs; Knowledge; Lead; Libraries; Malignant Neoplasms; Manuscripts; Modeling; Molecular Genetics; Molecular Probes; Organoids; Paper; Pharmaceutical Preparations; Pharmacology; Play; Postdoctoral Fellow; Research; Research Personnel; Role; Scientist; Services; Small Interfering RNA; Technology; Therapeutic; Training; Work; anticancer research; base; cancer cell; career development; design; drug discovery; functional genomics; graduate student; high throughput screening; high-throughput drug screening; innovation; instrumentation; meetings; member; new therapeutic target; novel; programs; screening; skills; stem; success; symposium

Project Summary: The Vanderbilt-Ingram Cancer Center (VICC) is an NCI-designated Comprehensive Cancer Center with over 270 members focused on cancer-related research. The Vanderbilt Institute of Chemical Biology (VICB) High- Throughput Screening (HTS) core facility was established to provide screening-based services for investigators for molecular probe and pharmacological discovery. Dr. Joshua Bauer plays an integral role in the interface between the cancer research and chemical biology programs at Vanderbilt. He has a strong background in cancer biology, pharmacology, and biochemistry. His main goal is to use chemical genomic approaches, including functional genomics screening and high-content imaging, to identify novel drug targets and to better understand the molecular and genetic mechanisms that underlie how cancer cells respond to therapeutics. To achieve this goal his cancer-related projects within the HTS facility are focused on three areas: 1) compound/drug library screening (i.e., HTS), 2) functional genomics (siRNA/CRISPR) library screening, and 3) high-content screening (HCS) and analysis. To date, Dr. Bauer has provided support and intellectual contributions to over 80 HTS projects, including collaborations with at least 41 Cancer Center members, including 31 that are NCI funded. These continued collaborations have allowed him to develop innovative assays and novel screening projects that contribute to the success of the Vanderbilt HTS core and cancer research program. His vital role and success stems from his ability to conceive, collaborate, design and perform screens, and intellectually contribute to projects, grant proposals, and manuscripts. In addition, through participation in conferences, meetings and workshops Dr. Bauer strives to bring state-of-the-art technologies and ideas to the Vanderbilt HTS facility. The blend of his skills, expertise, and knowledge provide a unique role within Vanderbilt to mend cancer research, chemical biology, genomics, drug discovery, and translational drug investigation. Through his previously funded R50 award, Dr. Bauer has already further advanced his areas of focus in HTS and his career development. So far on the award (2016-20), he has been co-authored on 11 papers, has supported 38 cancer-related grant proposals, supported and trained over 50 graduate students and postdocs on HTS instrumentation or software, has developed several novel functional genomics screens (CRISPR and ORFeome), and has pioneered several high-throughput 3D organoid models for high-content drug screening. Dr. Bauer has become a member of the NCI- Chemical Biology Consortium where he has been exposed to world-class drug discovery experts. Finally, the results of Dr. Bauer's work and collaborations have influenced the design of clinical trials, initiated sponsored research, and has led to lead molecules for further development. Therefore, Dr. Bauer's continued role as a Cancer Pharmacologist & HTS Scientist is completely indispensable to the cancer research program at Vanderbilt.

项目概要： 范德比尔特-英格拉姆癌症中心 (VICC) 是 NCI 指定的综合癌症中心，拥有超过 270 名成员专注于癌症相关研究。范德比尔特化学生物学研究所 (VICB) High- 建立通量筛选（HTS）核心设施，为研究者提供基于筛选的服务 用于分子探针和药理学发现。 Joshua Bauer 博士在界面中发挥着不可或缺的作用 范德比尔特大学的癌症研究和化学生物学项目之间。他拥有深厚的背景 癌症生物学、药理学和生物化学。他的主要目标是使用化学基因组方法， 包括功能基因组学筛选和高内涵成像，以确定新的药物靶点并更好地 了解癌细胞如何响应治疗的分子和遗传机制。到 为了实现这一目标，他在 HTS 设施内的癌症相关项目主要集中在三个领域：1) 化合物/药物 文库筛选（即 HTS），2) 功能基因组学 (siRNA/CRISPR) 文库筛选，以及 3) 高内涵 筛选（HCS）和分析。迄今为止，鲍尔博士已为 80 多名 HTS 项目，包括与至少 41 个癌症中心成员的合作，其中 31 个是由 NCI 资助的。 这些持续的合作使他能够开发创新的检测方法和新颖的筛选项目 有助于范德比尔特 HTS 核心和癌症研究项目的成功。他的重要作用和 成功源于他构思、协作、设计和执行屏幕以及智力贡献的能力 项目、拨款提案和手稿。此外，通过参加大会、会议和 Bauer 博士致力于将最先进的技术和理念引入范德比尔特 HTS 设施。这 他的技能、专业知识和知识相结合，在范德比尔特大学发挥着独特的作用，以改进癌症研究， 化学生物学、基因组学、药物发现和转化药物研究。通过他之前的资助 获得 R50 奖项后，Bauer 博士已经进一步推进了他在 HTS 的关注领域和职业发展。所以 迄今为止（2016-20），他已共同撰写了 11 篇论文，并支持了 38 项与癌症相关的资助 提案，支持并培训了 50 多名 HTS 仪器或软件的研究生和博士后， 开发了多种新型功能基因组筛选（CRISPR 和 ORFeome），并开创了多项 用于高内涵药物筛选的高通量 3D 类器官模型。 Bauer 博士已成为该组织的成员 NCI（化学生物学联盟），在那里他接触到了世界一流的药物发现专家。最后， Bauer 博士的工作和合作成果影响了临床试验的设计，发起了赞助 研究，并导致了进一步发展的先导分子。因此，鲍尔博士继续担任 癌症药理学家和 HTS 科学家对于癌症研究项目是完全不可或缺的 范德比尔特。